Monitor for any future material changes to the board or strategy. This filing is routine and does not warrant any trading action.
PCVX drugs
PCVX drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 24 $53.87entry
- T+1 · 5mo ago −0.35%α −0.50% · $53.68
- T+5 · 5mo ago +4.10%α +2.40% · $56.08
- T+20 · 4mo ago +3.95%α +2.02% · $56.00
- T+60 · 2mo ago +12.07%α +9.23% · $60.37
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Vaxcyte announced the retirement of board member Jacks Lee and the appointment of Moncef Slaoui as an independent Class II director, effective June 17, 2026. Dr. Slaoui will receive standard non-employee director compensation, including an annual equity grant currently valued at $430,000. This is a routine governance filing with no material financial or operational impact.
Key Facts
- Director Jacks Lee retired effective June 17, 2026; will remain as a consultant on supply and manufacturing.
- Moncef Slaoui appointed as an independent Class II director; term expires at the 2028 annual meeting.
- Dr. Slaoui receives standard director compensation; annual equity grant is currently set at $430,000.
Financial Impact
No material financial impact. Dr. Slaoui's annual director equity grant is $430,000, which is immaterial relative to Vaxcyte's $7.5B market cap.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001649094-26-000026 |
| Document: 0001649094-26-000026-index-headers.html | 0001649094-26-000026 |
| Document: 0001649094-26-000026-index.html | 0001649094-26-000026 |
| Document: 0001649094-26-000026.txt | 0001649094-26-000026 |
Track record
29 reports on PCVX
5 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +10.87% at T+5 after the Oct 8, 2026 report. 5 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $62.40 Now $63.37 +1.55% settles Dec 15
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $64.69 Now $63.37 −2.04% settles Dec 11
- Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $63.89 Now $63.37 −0.81% settles Dec 7
- Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $63.89 Now $63.37 −0.81% settles Dec 7
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $61.92 Now $63.37 +2.34% settles Dec 4
- Nov 4, 202612d ago 8-K Neutral 5/10 Entry $61.92 Now $63.37 +2.34% settles Dec 4
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $60.81 Now $63.37 +4.21% settles Dec 2
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $60.81 Now $63.37 +4.21% settles Dec 2
- Oct 9, 20265w ago 8-K Bearish 6/10 Entry $70.65 to $67.53 Now $63.37 +10.30% ▲ +4.42% +1.15% vs SPY
- Oct 8, 20265w ago 424B5 Bearish 6/10 Entry $71.38 to $63.89 Now $63.37 +11.22% ▲ +10.49% +4.93% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers